Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
Open Access
- 3 February 2025
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 43 (2) , e70042
Abstract
This multicenter real‐world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara‐R). The majority were under 70 years old (60.8%), predominantly female (56.9%), and heavily pretreated, with 74.5% being triple‐class refractory (TCR); 32.1% of the 28 patients with cytogenetic data had high‐risk abnormalities. The overall response rate (ORR) was 56.9%, including 3 patients with stringent complete response (sCR), 4 with CR, and 7 with very good partial response (VGPR). Neither age, number of prior therapies, TCR status, nor time from Dara refractoriness to IsaPd initiation significantly affected response rates.Median progression‐free survival (PFS) was 5.8 months, with a 12‐month PFS probability of 30.6%. Baseline hemoglobin (Hb) levels were a key predictor of PFS: patients with Hb < 11.8 g/L had a 3.5‐fold increased risk of progression, with a median PFS of 4.6 months compared to 22 months in those with higher Hb.Median overall survival (OS) was 21.0 months, with a 12‐month OS probability of 63.4%. Lower Hb levels (< 11 g/L) were associated with a tenfold increased risk of mortality.Among the 28 patients who underwent FISH analysis, while no significant difference in mortality risk was observed, those with high‐risk cytogenetic abnormalities exhibited a nearly tenfold increased risk of disease progression.These results suggest that IsaPd offers a meaningful option for Dara‐R patients, with Hb levels serving as a critical predictor of both PFS and OS. However, PFS remains modest, underscoring the need for novel combination therapies.Keywords
This publication has 34 references indexed in Scilit:
- Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma CellsFrontiers in Immunology, 2020
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyThe Lancet, 2019
- Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patientsCancer, 2019
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia, 2019
- Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practiceHealth Science Reports, 2018
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceFrontiers in Immunology, 2018
- Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myelomaBlood Advances, 2017
- Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agentsLeukemia, 2011
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- International uniform response criteria for multiple myelomaLeukemia, 2006